Pacific Biosciences of California (PACB) Competitors

$1.26 +0.08 (+6.30%)

As of 01:54 PM Eastern

PACB vs. TXG, HBIO, LMNX, TMO, and WAT

Should you buy Pacific Biosciences of California stock or one of its competitors? MarketBeat compares Pacific Biosciences of California with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pacific Biosciences of California include 10x Genomics (TXG), Harvard Bioscience (HBIO), Defiance Daily Target 2X Long LMND ETF (LMNX), Thermo Fisher Scientific (TMO), and Waters (WAT).

How does Pacific Biosciences of California compare to 10x Genomics?

10x Genomics (NASDAQ:TXG) and Pacific Biosciences of California (NASDAQ:PACB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

84.7% of 10x Genomics shares are held by institutional investors. 8.8% of 10x Genomics shares are held by company insiders. Comparatively, 2.5% of Pacific Biosciences of California shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

10x Genomics presently has a consensus price target of $23.17, suggesting a potential downside of 5.09%. Pacific Biosciences of California has a consensus price target of $1.83, suggesting a potential upside of 44.93%. Given Pacific Biosciences of California's higher possible upside, analysts plainly believe Pacific Biosciences of California is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$638.78M	4.85	-$43.54M	-$0.17	N/A
Pacific Biosciences of California	$160.03M	2.46	-$546.38M	-$0.43	N/A

10x Genomics has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.4, suggesting that its stock price is 140% more volatile than the broader market.

10x Genomics has a net margin of -3.55% compared to Pacific Biosciences of California's net margin of -80.35%. 10x Genomics' return on equity of -2.86% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-3.55%	-2.86%	-2.23%
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%

In the previous week, 10x Genomics had 1 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 3 mentions for 10x Genomics and 2 mentions for Pacific Biosciences of California. 10x Genomics' average media sentiment score of 0.19 beat Pacific Biosciences of California's score of 0.00 indicating that 10x Genomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacific Biosciences of California	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

10x Genomics beats Pacific Biosciences of California on 13 of the 16 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Harvard Bioscience?

Harvard Bioscience (NASDAQ:HBIO) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap life sciences tools & services companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Harvard Bioscience has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$86.55M	0.29	-$56.70M	-$2.17	N/A
Pacific Biosciences of California	$160.03M	2.46	-$546.38M	-$0.43	N/A

In the previous week, Pacific Biosciences of California had 1 more articles in the media than Harvard Bioscience. MarketBeat recorded 2 mentions for Pacific Biosciences of California and 1 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 0.25 beat Pacific Biosciences of California's score of 0.00 indicating that Harvard Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harvard Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacific Biosciences of California	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Harvard Bioscience has a net margin of -11.44% compared to Pacific Biosciences of California's net margin of -80.35%. Harvard Bioscience's return on equity of -25.78% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-11.44%	-25.78%	-4.37%
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%

Harvard Bioscience currently has a consensus price target of $6.00, suggesting a potential upside of 9.59%. Pacific Biosciences of California has a consensus price target of $1.83, suggesting a potential upside of 44.93%. Given Pacific Biosciences of California's higher possible upside, analysts plainly believe Pacific Biosciences of California is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

80.9% of Harvard Bioscience shares are held by institutional investors. 20.3% of Harvard Bioscience shares are held by company insiders. Comparatively, 2.5% of Pacific Biosciences of California shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Harvard Bioscience has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.4, meaning that its share price is 140% more volatile than the broader market.

Summary

Harvard Bioscience beats Pacific Biosciences of California on 9 of the 15 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Defiance Daily Target 2X Long LMND ETF?

Pacific Biosciences of California (NASDAQ:PACB) and Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Pacific Biosciences of California has a beta of 2.4, meaning that its share price is 140% more volatile than the broader market. Comparatively, Defiance Daily Target 2X Long LMND ETF has a beta of -10.89, meaning that its share price is 1,189% less volatile than the broader market.

Defiance Daily Target 2X Long LMND ETF has a net margin of 5.39% compared to Pacific Biosciences of California's net margin of -80.35%. Defiance Daily Target 2X Long LMND ETF's return on equity of 4.66% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%
Defiance Daily Target 2X Long LMND ETF	5.39%	4.66%	2.91%

Defiance Daily Target 2X Long LMND ETF has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Defiance Daily Target 2X Long LMND ETF, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.03M	2.46	-$546.38M	-$0.43	N/A
Defiance Daily Target 2X Long LMND ETF	$437.66M	0.01	$15.17M	$0.51	26.18

87.8% of Defiance Daily Target 2X Long LMND ETF shares are owned by institutional investors. 2.5% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 6.6% of Defiance Daily Target 2X Long LMND ETF shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Pacific Biosciences of California presently has a consensus price target of $1.83, suggesting a potential upside of 44.93%. Given Pacific Biosciences of California's stronger consensus rating and higher possible upside, research analysts plainly believe Pacific Biosciences of California is more favorable than Defiance Daily Target 2X Long LMND ETF.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Defiance Daily Target 2X Long LMND ETF	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Pacific Biosciences of California had 2 more articles in the media than Defiance Daily Target 2X Long LMND ETF. MarketBeat recorded 2 mentions for Pacific Biosciences of California and 0 mentions for Defiance Daily Target 2X Long LMND ETF. Pacific Biosciences of California's average media sentiment score of 0.00 equaled Defiance Daily Target 2X Long LMND ETF'saverage media sentiment score.

Company	Overall Sentiment
Pacific Biosciences of California	Neutral
Defiance Daily Target 2X Long LMND ETF	Neutral

Summary

Defiance Daily Target 2X Long LMND ETF beats Pacific Biosciences of California on 9 of the 15 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Thermo Fisher Scientific?

Thermo Fisher Scientific (NYSE:TMO) and Pacific Biosciences of California (NASDAQ:PACB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Thermo Fisher Scientific has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Thermo Fisher Scientific	$44.56B	3.75	$6.70B	$18.19	24.74
Pacific Biosciences of California	$160.03M	2.46	-$546.38M	-$0.43	N/A

Thermo Fisher Scientific presently has a consensus target price of $616.10, suggesting a potential upside of 36.91%. Pacific Biosciences of California has a consensus target price of $1.83, suggesting a potential upside of 44.93%. Given Pacific Biosciences of California's higher possible upside, analysts clearly believe Pacific Biosciences of California is more favorable than Thermo Fisher Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Thermo Fisher Scientific	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Thermo Fisher Scientific had 54 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 56 mentions for Thermo Fisher Scientific and 2 mentions for Pacific Biosciences of California. Thermo Fisher Scientific's average media sentiment score of 1.23 beat Pacific Biosciences of California's score of 0.00 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Thermo Fisher Scientific	40 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacific Biosciences of California	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.2% of Thermo Fisher Scientific shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by company insiders. Comparatively, 2.5% of Pacific Biosciences of California shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Thermo Fisher Scientific has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.4, suggesting that its share price is 140% more volatile than the broader market.

Thermo Fisher Scientific has a net margin of 15.15% compared to Pacific Biosciences of California's net margin of -80.35%. Thermo Fisher Scientific's return on equity of 16.86% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Thermo Fisher Scientific	15.15%	16.86%	8.15%
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%

Summary

Thermo Fisher Scientific beats Pacific Biosciences of California on 14 of the 17 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Waters?

Pacific Biosciences of California (NASDAQ:PACB) and Waters (NYSE:WAT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

94.0% of Waters shares are held by institutional investors. 2.5% of Pacific Biosciences of California shares are held by insiders. Comparatively, 0.3% of Waters shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Pacific Biosciences of California presently has a consensus price target of $1.83, suggesting a potential upside of 44.93%. Waters has a consensus price target of $396.00, suggesting a potential upside of 16.43%. Given Pacific Biosciences of California's higher probable upside, equities analysts clearly believe Pacific Biosciences of California is more favorable than Waters.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Waters	0 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.75

Pacific Biosciences of California has a beta of 2.4, indicating that its stock price is 140% more volatile than the broader market. Comparatively, Waters has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

In the previous week, Waters had 2 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 4 mentions for Waters and 2 mentions for Pacific Biosciences of California. Waters' average media sentiment score of 0.86 beat Pacific Biosciences of California's score of 0.00 indicating that Waters is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Waters	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Waters has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.03M	2.46	-$546.38M	-$0.43	N/A
Waters	$3.17B	10.55	$642.63M	$7.87	43.22

Waters has a net margin of 11.91% compared to Pacific Biosciences of California's net margin of -80.35%. Waters' return on equity of 15.60% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%
Waters	11.91%	15.60%	8.90%

Summary

Waters beats Pacific Biosciences of California on 14 of the 17 factors compared between the two stocks.

Get Pacific Biosciences of California News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PACB vs. The Competition

Export

Metric	Pacific Biosciences of California	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$391.36M	$6.93B	$6.30B	$12.21B
Dividend Yield	N/A	1.70%	2.80%	5.36%
P/E Ratio	-2.93	49.61	20.79	25.32
Price / Sales	2.46	72.33	518.79	71.95
Price / Cash	1.46	24.40	43.18	55.00
Price / Book	126.50	6.41	9.96	6.97
Net Income	-$546.38M	$158.81M	$3.54B	$334.92M
7 Day Performance	4.55%	1.30%	-0.19%	-0.98%
1 Month Performance	-26.88%	-1.66%	-0.63%	0.43%
1 Year Performance	28.92%	1.20%	34.10%	33.61%

Pacific Biosciences of California Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PACB Pacific Biosciences of California	1.5241 of 5 stars	$1.27 +6.3%	$1.83 +44.9%	+16.7%	$391.36M	$160.03M	N/A	730
TXG 10x Genomics	1.5837 of 5 stars	$21.45 +1.2%	$23.17 +8.0%	+164.1%	$2.69B	$642.82M	N/A	1,240	Analyst Downgrade
HBIO Harvard Bioscience	2.6692 of 5 stars	$5.00 -4.8%	$6.00 +20.0%	+60.5%	$23.68M	$86.55M	N/A	490
LMNX Defiance Daily Target 2X Long LMND ETF	N/A	$12.33 +12.0%	N/A	N/A	$4.07M	$437.66M	24.18	1,325	Gap Down
TMO Thermo Fisher Scientific	4.8494 of 5 stars	$442.16 +0.9%	$616.10 +39.3%	+9.3%	$162.90B	$44.56B	24.31	125,000	Positive News Dividend Announcement

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PACB) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pacific Biosciences of California (PACB) Competitors

PACB vs. TXG, HBIO, LMNX, TMO, and WAT

How does Pacific Biosciences of California compare to 10x Genomics?

Summary

How does Pacific Biosciences of California compare to Harvard Bioscience?

Summary

How does Pacific Biosciences of California compare to Defiance Daily Target 2X Long LMND ETF?

Summary

How does Pacific Biosciences of California compare to Thermo Fisher Scientific?

Summary

How does Pacific Biosciences of California compare to Waters?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB vs. The Competition

Pacific Biosciences of California Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pacific Biosciences of California (PACB) Competitors

PACB vs. TXG, HBIO, LMNX, TMO, and WAT

How does Pacific Biosciences of California compare to 10x Genomics?

Do institutionals and insiders believe in TXG or PACB?

Do analysts recommend TXG or PACB?

Which has higher valuation & earnings, TXG or PACB?

Which has more volatility and risk, TXG or PACB?

Is TXG or PACB more profitable?

Does the media refer more to TXG or PACB?

Summary

How does Pacific Biosciences of California compare to Harvard Bioscience?

Which has higher valuation and earnings, HBIO or PACB?

Does the media refer more to HBIO or PACB?

Is HBIO or PACB more profitable?

Do analysts recommend HBIO or PACB?

Do insiders & institutionals hold more shares of HBIO or PACB?

Which has more volatility and risk, HBIO or PACB?

Summary

How does Pacific Biosciences of California compare to Defiance Daily Target 2X Long LMND ETF?

Which has more risk & volatility, PACB or LMNX?

Is PACB or LMNX more profitable?

Which has higher earnings & valuation, PACB or LMNX?

Do insiders and institutionals hold more shares of PACB or LMNX?

Do analysts prefer PACB or LMNX?

Does the media refer more to PACB or LMNX?

Summary

How does Pacific Biosciences of California compare to Thermo Fisher Scientific?

Which has better earnings and valuation, TMO or PACB?

Do analysts prefer TMO or PACB?

Does the media favor TMO or PACB?

Do insiders and institutionals hold more shares of TMO or PACB?

Which has more risk & volatility, TMO or PACB?

Is TMO or PACB more profitable?

Summary

How does Pacific Biosciences of California compare to Waters?

Do insiders & institutionals have more ownership in PACB or WAT?

Do analysts prefer PACB or WAT?

Which has more volatility & risk, PACB or WAT?

Does the media prefer PACB or WAT?

Which has stronger earnings and valuation, PACB or WAT?

Is PACB or WAT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB vs. The Competition

Pacific Biosciences of California Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools